Stock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 Design
Recursion Pharmaceuticals stock rose 4% after reaching FDA alignment on the Phase 3 trial design for REC-4881, its AI-enabled treatment for familial adenomatous polyposis. The FDA accepted polyp excision as part of the primary endpoint, potentially allowing for a shorter, less costly trial. However, the Phase 3 trial won't begin until late 2027, requiring patient investors to wait for actual trial results.
